Cost-effectiveness of carbamazepine in epilepsy

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 6, Issue 1, 2006, Pages 13-18

  Heaney, Dominic ^a   Sander, Josemir W ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Carbamazepine; Cost effectiveness; Economic modeling; Epilepsy; Generic prescribing

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; GENERIC DRUG; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

BIOEQUIVALENCE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG SUBSTITUTION; DRUG USE; EPILEPSY; FOCAL EPILEPSY; HUMAN; MONOTHERAPY; PRESCRIPTION; QUALITY OF LIFE; REVIEW; TABLET FORMULATION; UNSPECIFIED SIDE EFFECT;

EID: 33646108590     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.6.1.13     Document Type: Review

References (38)

1. NICE. The diagnosis and care of children and adults with epilepsy. London, NICE, Report No.: CG20 (2004).
2. Heaney D, Shorvon S, Sander JW et al. A cost minimisation study comparing the use of anti-epileptic drugs in newly diagnosed epilepsy in 11 European countries. Epilepsia 41 (Suppl. 5), S37-S44 (2000).
3. Heaney DC, Shorvon SD, Sander JW. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia 39 (Suppl. 3), S19-S25 (1998).
4. Shakespeare A, Simeon G. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK. Seizure 7(2), 119-125 (1998).
5. Bryant J, Stein K. Lamotrigine as monotherapy in the treatment of partial epilepsy. Wessex Institute for Health Research and Development (1998).
6. Remak E, Hutton J, Price M, Peeters K, Adriaenssen I. A Markov model of treatment of newly diagnosed epilepsy in the UK. An initial assessment of cost-effectiveness of topiramate. Eur. J. Health. Econ. 4(4), 271-278 (2003).
7. Hawkins N, Epstein D, Drummond M et al. Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model. Med Decis. Making 25(5), 493-510 (2005).
8. Schachter SC, Sommerville KW, Ryan JE. A cost-effectiveness analysis of tiagabine, phenytoin, and carbamazepine adjunctive therapy for patients with complex partial seizures. Neurology 52 (Suppl. 6), A143 (1999).
9. Young JD. FDA policy on generic anticonvulsants. Scrip 1469, 28 (1989).
10. British Pharmacopeia Commission. British Pharmacopaeia. The Stationary Office (2005).
11. Commission of the European Communities. Directive 91/356/EEC. Off J. Eur. Communities 142(11) (1991).
12. Mahmood I, Chamberlin N, Tammara V. A limited sampling approach in bioequivalence studies. Ther. Drug Monit. 19, 413-419 (1997).
13. Bialer M, Arcavi L, Sussan S et al. Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine. Epilepsy Res. 32, 371-378 (1998).
14. Bialer M, Yacobi A, Moros D, Levitt B, Houle JM, Munsaka MS. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. Epilepsia 39(5), 513-519 (1998).
15. Crawford P, Hall WW, Chappell B, Collings JA, Steward A. Generic prescribing for epilepsy: is it safe? Seizure 5, 1-5 (1996).
16. Beach R, Reading R. Generic prescribing for epilepsy. Is it safe? Seizure 6, 327 (1997).
17. Argumosa A, Herranz JL. The clinical and economic impact of generic drugs in the treatment of epilepsy. Rev. Neurol. 41(1), 45-49 (2005).
18. Spitz MC. Injuries and death as a consequence of seizures in people with epilepsy. Epilepsia 39(8), 904-907 (1998).
19. Garnett WR, Gilbert TD, O'Connor P. Patterns of care, outcomes, and direct health plan costs of anti-epileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations. Clin. Ther. 27(7), 1092-1103 (2005).
20. Audit Commission. A prescription for improvement: towards more rational prescribing in general practice. London: HMSO (1999).
21. Cohen LJ, Shelton RC, Brown B et al. The use of generic mood stabilizers. J Clin. Psych. 15(4), 1-38 (1997).
22. French JA. The long-term therapeutic management of epilepsy. Ann. Intern. Med. 120, 411-422 (1994).
23. McGill I. Prescribing anticonvulsants. The Pharmaceutical Journal 261, 793 (1998).
24. Neuhauser M, Frazier J. Should generic carbamazepine be substituted for Tegretol? Premier Purchasing partners, 1-5 (1996).
25. Nuwer MR, Browne TR, Dodson WE et al. Generic substitutions for anti-epileptic drugs. Neurology 40, 1647-1651 (1990).
26. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: generic substitution for anti-epileptic medication. Neurology 40, 1641-1643 (1990).
27. Besag FM. Is generic prescribing acceptable in epilepsy? Drug Saf. 23(3), 173-182 (2000).
28. Jobst BC, Holmes GL. Prescribing anti-epileptic drugs: should patients be switched on the basis of cost? CNS Drugs 18(10), 617-628 (2004).
29. Petersen KU. Original brands and generic preparations. Med. Klin. (Munich) 95(1), 26-30 (2000).
30. Oles KS, Penry JK, Smith LD, Anderson RL, Dean JC, Riela AR. Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology 42, 1147-1153 (1992).
31. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of anti-epileptic drugs. Epilepsia 45(11), 1330-1337 (2004).
32. Miller AD, Krauss GL, Hamzeh FM. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol. Scand. 109(6), 374-377 (2004).
33. Ficker DM, Privitera M, Krauss G, Kanner A, Moore JL, Glauser T. Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Neurology 65(4), 593-595 (2005).
34. Heaney DC, Sander JW, Shorvon SD. Comparing the cost of epilepsy across eight European countries. Epilepsy Res. 43(2), 89-95 (2001).
35. Brodie MJ, Overstall PW, Giorgi L. Multi-centre, double-blind, randomised comparision between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res. 37, 81-87 (1999).
36. Morrow JI, Russell A, Gutherle E et al. Malformation risks of anti-epileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry 12, jnnp (2005).
37. Chisholm D, WHO. Cost-effectiveness of first-line anti-epileptic drug treatments in the developing world: a population-level analysis. Epilepsia 46(5), 751-759 (2005).
38. Kwan P. Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 45(9), 1141-1149 (2004).